Annette Langer-Gould, MD, PhD: No Increased Risk for Postpartum MS Relapses
August 13th 2019The regional lead in clinical and translational neuroscience at Kaiser Permanente spoke about the findings of a recent study of pregnancy in women with MS which showed no increased risk of relapse during the postpartum period.
CAG Repeat Length Predicts Huntington Disease Decline
August 13th 2019Using principal component analysis, the findings suggest that CAG repeat length strongly predict the rate of cognitive-motor decline in patients with Huntington disease, with higher CAG resulting in earlier and faster decline.
Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease
August 13th 2019The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of Alzheimer disease.
Neurofilament Light Prognostic Value in MS Is Limited on Individual Level
August 13th 2019Although the biomarker was associated with disease activity, its prognostic value on the individual patient level is still limited per these 10-year data of more than 600 patients with multiple sclerosis.
Nonmotor Parkinson Symptoms Impact Patient Quality of Life
August 12th 2019The director of the University of Southern Florida’s Parkinson's and Movement Disorders Center shared insight into the current focus on the nonmotor aspects of Parkinson care and the findings of a survey of patients and caregivers.
Exploring the Impact of Caregiver Depression on Patients With Dementia
August 12th 2019The neurohospitalist and assistant professor of neurology at the University of California San Francisco spoke about how caregiver depression is an important risk factor associated with increased healthcare use among individuals with dementia.
David Irwin, MD: Differentiating Dementias in Living Patients
August 12th 2019The assistant professor and cognitive neurologist at the University of Pennsylvania Frontotemporal Degeneration Center will share additional insights on Alzheimer disease at the upcoming International Congress on the Future of Neurology, taking place September 27-28, 2019 in New York City.
Smoking Cessation Success in Multiple Sclerosis Should Be a Priority
August 12th 2019The early career fellow in the Center for Health Equity at the Melbourne School of Population and Global Health at the University of Melbourne offered insight into the critical need for research and efforts to increase smoking cessation in those with multiple sclerosis.
Personal Devices May Aid in MCI and Alzheimer Dementia Identification
August 9th 2019Initial data from a feasibility study conducted with Apple devices and digital apps has shown the potential for these to be able to differentiate people with mild cognitive impairment and mild Alzheimer disease dementia.
Specialized Epilepsy Care Linked to Lower Premature Mortality
August 9th 2019Exposure to the care of either a neurologist or comprehensive epilepsy program epileptologist resulted in a significantly lower rate of premature mortality than that of those who were not, based on findings from a cohort of more than 20,000 cases.
Kathryn Davis, MD, MSTR: Off-Label Clobazam Use in Refractory Epilepsy
August 9th 2019The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania discussed the findings of a single-center review of off-label clobazam use for patients with drug-refractory epilepsy.
Diazepam Buccal Film Beneficial in Refractory Epilepsy With Seizure Clusters
August 8th 2019The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.
Kathryn Davis, MD, MSTR: Treatment Considerations for Women With Epilepsy
August 8th 2019The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania shared insight into the prioritization of women with epilepsy who may intend to get pregnant.
Idiopathic REM Sleep Behavior Disorder Distinct From Narcolepsy-Associated Pathophysiology
August 8th 2019New study findings confirm that idiopathic rapid‐eye‐movements sleep behavior disorder and RBD secondary to narcolepsy type 1 can be identified via video‐polysomnography and skin biopsy for phosphorylated α‐synuclein deposits.
NORD and C-Path Announce Rare Diseases Data and Analytics Platform
August 8th 2019The Rare Disease Cures Accelerator-Data and Analytics Platform, aimed at accelerating the development of new therapies, will launch at a joint meeting between the Critical Path Institute and the National Organization for Rare Disorders on Tuesday, September 17 in Bethesda, Maryland.
Sarah Wilson, PhD: Long-Term Social Outcomes of Epilepsy Surgery
August 7th 2019The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the results of a study she and colleagues conducted in which they mapped the long-term social outcomes of patient post-epilepsy surgery.
CGRP Migraine Medications Improve the Treatment Paradigm
August 7th 2019The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in the armamentarium, and how therapies like eptinezumab can improve patients’ belief in their physician’s ability to help.
Gait Changes Can Predict Parkinson Conversion From Prodromal Phase
August 6th 2019The professor of neurology at University Medical Center Schleswig‐Holstein, and member of the department of neurodegenerative diseases at University Hospital Tübingen shared insight into the quantitative gait characteristics measured by wearable devices which can play an important role in the identification of prodromal Parkinson disease and its progression.
Galcanezumab Reduces Monthly Migraine Days in Episodic, Chronic Migraine
August 5th 2019The findings demonstrated that the galcanezumab group—made up of those with both chronic and episodic migraine—experienced a 4.1-day reduction in monthly migraine headache days compared to a 1.0-day reduction with placebo.